Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma

NCT02649478 is registered in ClinicalTrials.gov with Roxane Laboratories as lead sponsor.

NCT NCT02649478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02649478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Lead sponsor
Roxane Laboratories
Phase
Not applicable
Overall status
Completed
Start date
August 31, 2014
Completion date
November 30, 2015
Enrollment
1,430 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

asthma